Navigation Links
ACORN Continues Success in Oncology Data Warehousing With Accumulation of Nearly 50 Million Data Observations
Date:6/16/2008

MEMPHIS, Tenn., June 16 /PRNewswire/ -- Accelerated Community Oncology Research Network(TM), an oncology-focused CRO and research network, announced today that its Oncology Data Warehouse has accumulated nearly 50 million data observations from over 110,000 oncology patients contained in its data warehouse. Integrating patient-reported outcomes (PROs), electronic medical records (EMR), claims data, and laboratory information systems, garnered from community oncology practices nationwide where 85% of cancer care is provided, the warehouse contains demographically diverse data, offering reliable information on treatments and outcomes to payers, financial institutions, pharmaceutical / biotech companies, and community oncology practices.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071112/CLM151LOGO )

"Our data warehouse is now mature enough to support longitudinal or cross- sectional analyses comparing practice patterns, toxicity, and outcomes in large groups of patients undergoing treatment for a broad range of tumor types," according to Ed Stepanski, Ph.D., Chief Operating Officer. "Additionally, several years of archived PACE System PROs provide a critical component to our Oncology Data Warehouse, allowing us to systematically analyze patients' symptom burden and quality of life, making our warehouse unique among all oncology data repositories."

Analytic data from this large-scale oncology data repository has been presented at many major oncology-related conferences and published in peer- reviewed medical journals worldwide. Furthering the field of oncology health informatics, ACORN's data warehouse has been used in numerous projects that address quality of care, patients' quality of life, overall health outcomes and the cost of care.

"Determining the most effective and least toxic treatment regimens in actual clinical practice, as opposed to a clinical trial, is a valuable end result from the data warehouse," observes Steve Coplon, CEO. "ACORN will soon double the number of unique patients in the warehouse. The warehouse runs as close to real time as is needed for projects we conduct."

ACORN will exhibit at the annual Drug Information Association meeting in Boston, June 22-25, 2008. Senior level ACORN executives will be present to discuss ACORN's Oncology Data Warehouse as well as its CRO services, Guardian EDC, and network of community oncology practices. For additional information visit http://www.ACORNresearch.net or contact Liz Conway, Director of Marketing and Corporate Services, 901-259-0878.

Accelerated Community Oncology Research Network, Inc. (ACORN)

ACORN focuses on oncology exclusively. ACORN offers centralized clinical trial services, scientific analysis, and is a full-service Clinical Research Organization (CRO), providing contract and budgeting services; fostering accrual of subjects at the site level; collecting data and monitoring its accuracy; and working seamlessly with both trial sponsors and participating practices.

Contact Information:

Liz Conway

(901) 435-5570

lconway@sosacorn.com

http://www.ACORNresearch.net

Deborah D. Coble

901-683-0055x1312

dcoble@sosacorn.com


'/>"/>
SOURCE Accelerated Community Oncology Research Network, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ACORN Presents Findings of Collaborative Metastatic Colorectal Cancer Research
2. ACORNs Oncology-focused Contract Research Organization Exceeds Projections
3. AlphaVax Continues to Expand the Use of Its Vaccine Platform
4. Replidyne Discontinues Phase III Trial
5. Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
6. Medarex Announces Ipilimumab Program Continues to Move Forward
7. Carpet One Floor & Home Continues Making Dramatic Strides in Funding Breast Cancer Research and Awareness
8. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
9. Phase I and Phase I/II DCVax(R)-Brain Data Continues to Show Significantly Improved Survival Rates for Brain Cancer Patients
10. Bone Mineral Content Continues to Increase in Obese Adolescents During Weight Loss
11. The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... MINNEAPOLIS , April 20, 2017  Cogentix ... company focused on providing the Urology, Uro/Gyn and ... reported that Ash Keswani has joined the Company ... In this newly created position, Mr. Keswani will ... and CEO. "Our organization is delighted ...
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Market and Increasing Usage of Complex Biologics during the Forecast Period" ... ... 20 Billion in 2015 to around USD 26 Billion by 2020. ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ...
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
Breaking Medicine Technology:
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... ... celebrate the profession and recognize the positive impact veterinarians have on animal health ... and the World Organization for Animal Health (OIE) choose a theme each year ...
(Date:4/28/2017)... NC (PRWEB) , ... April 28, 2017 , ... ... announce its new partnership with the Home Care Association of America (HCAOA). This ... and Private Duty Accreditation services, as well as discounts on Accreditation University (AU) ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Beginning in ... of their formulas. This begins with the popular ClearLungs Extra Strength formula. To ensure ... changing the formula in the following ways:, , Removal of ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... distribution of the GlycoMark test throughout the Northeast U.S. , GlycoMark is ... with diabetes. The GlycoMark test provides a clinically proven one- to two-week measure ...
(Date:4/28/2017)... Fairfax, VA (PRWEB) , ... April 28, 2017 , ... ... elected volunteer board members and officers for 2017-2018. The annual board election process has ... serving on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, ...
Breaking Medicine News(10 mins):